Intal and Zoledronic acid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Intal (cromolyn sodium) and Zoledronic acid (zoledronic acid). Common drug interactions include bronchitis among females and hypoxia among males.

The phase IV clinical study analyzes what interactions people have when they take Intal and Zoledronic acid. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Intal?

Intal has active ingredients of cromolyn sodium. It is often used in asthma. eHealthMe is studying from 1,621 Intal users. Check the latest studies of Intal.

What is Zoledronic acid?

Zoledronic acid has active ingredients of zoledronic acid. eHealthMe is studying from 28,485 Zoledronic acid users. Check the latest studies of Zoledronic acid.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

21 people who take Intal and Zoledronic acid together, and have interactions are studied.

Intal and Zoledronic acid drug interactions.

What are the common drug interactions of Intal and Zoledronic Acid, by gender? *:

female:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

male:

  1. Hypoxia (low oxygen in tissues)
  2. Organising pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue)
  3. Mouth ulceration (mouth ulcers)
  4. Oral discomfort (pain or irritation in mouth)
  5. Salivary hypersecretion (excess saliva secretion)
  6. Activities of daily living impaired
  7. Malaise (a feeling of general discomfort or uneasiness)
  8. Pneumonia influenzal (the flu with pneumonia)
  9. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  10. Hypoaesthesia (reduced sense of touch or sensation)

What are the common drug interactions of Intal and Zoledronic Acid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  2. Hypoaesthesia (reduced sense of touch or sensation)
  3. Pain
  4. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  5. Wound secretion

40-49:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Glossodynia (a burning or painful sensation in the tongue)
  3. Lip dry
  4. Mouth ulceration (mouth ulcers)
  5. Oral discomfort (pain or irritation in mouth)
  6. Salivary hypersecretion (excess saliva secretion)
  7. Activities of daily living impaired

50-59:

n/a

60+:

  1. Hypoxia (low oxygen in tissues)
  2. Organising pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue)
  3. Pneumonia influenzal (the flu with pneumonia)
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 42.86%
  2. Seasonal Allergy (allergic condition due to certain season): 8 people, 38.10%
  3. Osteoporosis (bones weak and more likely to break): 8 people, 38.10%
  4. Migraine (headache): 8 people, 38.10%
  5. Irritable Bowel Syndrome: 8 people, 38.10%
  6. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 8 people, 38.10%
  7. Prostatic Disorder: 7 people, 33.33%
  8. Multiple Myeloma (cancer of the plasma cells): 6 people, 28.57%
  9. Cough: 3 people, 14.29%
  10. Adverse Event: 3 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Intal and Zoledronic acid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Intal and Zoledronic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Intal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zoledronic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Intal and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zoledronic acid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cromolyn sodium and zoledronic acid (the active ingredients of Intal and Zoledronic acid, respectively), and Intal and Zoledronic acid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: